On January 31, Celsion Corporation (CLSN) lost more than 80% of its value after its ThermoDox product failed to show statistical significance in a Phase 3 trial. Prior to this news, Celsion had become the stock-of-choice among those companies developing medical devices and new technologies in oncology. In just one year, its market cap grew from $70 million to $300 million as it quickly created excitement for the space. But since its failed study, the level of interest in the space has fallen, and investors are more skeptical that small medical device companies can succeed in large clinical studies.

In this piece I am looking at what might be the best news for a small medical device company since the Celsion disaster, and how this news might impact the rest of the space and the approach of companies in the space moving forward.

On Monday, BSD Medical Corporation (BSDM) traded

Investor and Analyst Update Conference Transcript

March 6, 2013, 2:00 PM ET

Executives

Tricia Ross - Vice President, Financial Profiles, Inc.

Butch Wolcott - President

William Barth - Chief Financial Officer

Sam Maravich - Vice President, Sales and Marketing

Analysts

Presentation

Operator

Good day, ladies and gentlemen. My name is Chris and I'll be your conference operator today. At this time, I would like to welcome everyone to the BSD Medical Investor and Analyst update call. All lines have been placed on mute to prevent any background noise. Just as a reminder this conference is being recorded today, Wednesday, March 6, 2013.

I would now like to turn the call over to Tricia Ross of Financial Profiles, please go ahead, ma'am.

Tricia Ross

Thank you, Chris. Good afternoon. I would like to thank everyone for joining us today and I want to welcome you to the

The following 5 biotech companies have strong catalysts and/or strong chart signals that indicate a trade to the long side could be in order. With the current choppy markets, opportunities for long trades are few and far between. I will give specifics for each company on why I believe they should provide a nice upside gain.

BSD Medical (BSDM) develops, manufactures, markets, and services systems to treat cancer and diseases using heat therapy delivered via focused radiofrequency and microwave energy. The company develops technology and products for thermal ablation and hyperthermia cancer therapy through various techniques, which include thermal ablation that ablates soft tissues at high temperatures through focused microwave energy.

The current options for cancer patients include the following:

• Surgery
• Ablation
• External Radiation
• Systemic Chemotherapy
• Embolization (chemo/radio)

With the use of BSD's ablation technology, cancer patients have the opportunity for a non-invasive alternative to open surgery.

There is a certain element of thrill and satisfaction that comes from buying small stocks with a great story. It is the same feeling that scouts get when searching for that next great league player. Trying to find the next big thing can be taxing on both your time and resources.

In addition to the amount of time it takes to investigate small stocks, good ideas are not always financially viable. Large corporations afraid of losing their market share are quick to employ a range of guerilla tactics to quash any new uprisings if they cannot buy them out. While innovation and imagination are the hallmarks of success, the mass public may not turn to new methods until necessity demands it.

For example, I love the concept of having a home roofed in new solar absorbing energy shingles, but Evergreen Solar (ESLR) is about to be de-listed as it files

When considering small cap investments, one important consideration is how long the company can survive without producing additional revenue. To measure this, we calculated the average quarterly operating expense over the last year for small cap companies (with market caps just above $100M). We then compared this number to the cash holdings of the firms.

All companies listed below have more than 4x the cash for their average quarterly operating expense, translating into coverage of more than four quarters of average quarterly operating expenses without the need for additional revenue.

Click to enlarge:


Do their cash holdings make these names trustworthy investments? Use this list as a starting-off point for your own analysis into small cap investments.

List sorted by cash/avg. quarterly operating expense.

1. Gold Reserve Inc. (GRZ): Gold Industry. Market cap of $103.44M. Current cash holdings at $60.45M vs. average quarterly operating expenses over the last four quarters at

by David Sterman

I'm a big fan of low-priced stocks -- especially those that are under $5 a share. At that level, most mutual fund managers are restricted from owning them. But if growth plans pan out and shares move above that threshold, those same fund managers then have the green light to buy in. And once they do, these stocks can keep moving even higher.

Among the various stock screens I maintain, one is for this low-priced group. I give it a fresh look every month or two to see if it's time to get excited about the names on this watch list. I try to calculate the upside I see for each name and put in extra work on the potentially big gainers. Here's my Fab-Five right now.

1. Biodel (Nasdaq: BIOD)

This has been a frustrating stock for many investors, but with a few breaks

The following is a list of stocks gaining downward momentum, i.e. have had bearish MACD crossovers over the last two days (based on the MACD (12,26,9) indicator). In addition, all of these stocks have seen a significant increase in shares shorted between 9/30 - 12/31.

Is this excessive pessimism justified, or will the inevitable short-covering provide support to these stocks? Full details below.

MACD signals sourced from Stockcharts.com, short trends data sourced from AOL Money.

Interactive Chart: Press Play to compare changes in analyst ratings over the last two years for the stocks mentioned below. Analyst ratings sourced from Zacks Investment Research. Note: The numbers on top of items represent the forward P/E ratio, if available.

The list has been sorted by the change in shares shorted over the last three months.

1. Universal Travel Group (UTA): Consumer Services Industry. Market cap of

By David Sterman

Despite economic challenges, the United States remains a compelling hotbed of innovation. So many items in everyday use -- especially in the field of medicine -- got their start here. The quest is always on to develop devices, drugs and services that help save money and boost the user's experience. And investors who get in early can be richly rewarded.

Of course, the path from idea to large-scale revenue can be excruciatingly slow at times. And up until now, these three companies were better known for consuming capital. But each of them has hit upon novel, potentially game-changing technologies that may eventually shower investors with riches.

BioLase Technologies (BLTI)
Nobody likes going to the dentist. Memories of a metal drill boring into our gums linger long, and it's often a reason why people don't go to the dentist as often as they should. But

Guest post by Pharmboy

BSD Medical (BSDM) develops, manufactures, markets and services medical systems that deliver precision-focused radio frequency (RF) or microwave energy into diseased sites of the body, heating them to specified temperatures as required by a variety of medical therapies. Their business objectives are to commercialize our products developed for the treatment of cancer and to further expand their systems to treat other diseases and medical conditions. Their product line for cancer therapy has been created to offer hospitals and clinics a complete solution for thermal treatment of cancer as provided through microwave/RF systems. Below are pictures of a few of their products.

BSD-500, BSD-2000, BSD-2000/MR/3D

BSD’s patented “phased-array” technology, the lifeblood of the MTX, generates heat that allows doctors to kill massive clusters of cancer cells. How does it work? Using focused radiofrequency or microwave energy, the tumor is heated to approximately 108°F. Heat can kill cancer

By Patrick Crutcher

We've been noticing a lot movement on several medical device companies. Since highlighting these to our premium subscribers, all the tickers have been moving upward, but there is more room to run.

Today, we want to briefly highlight a few more companies in this space that might spark some interest for investors. Most of the companies presented below have small floats(<50M shares), so they can move quickly.

First up, BSD Medical Corp. (NASDAQ: BSDM). Ever since obtaining approval for their MicroThermX Microwave Ablation System (MTX-180) in August, BSDM has gained over 500% and yet they still seem undervalued. The MTX-180 was designed to provide an improved ablation system targeted to the growing soft tissue ablation oncology market, a market expected to reach $2.0 billion. This news has been followed by a steady stream of good news including CE mark approval of the MTX-180 in the EU

The following is a list of small-cap stocks, with market caps ranging between $100M and $300M. All of these stocks are in rally mode, trading above their 20-day, 50-day and 200-day moving averages.

With the Fed obviously trying to inflate the stock market, equity investors might be looking to take on more risk in the short term. Hopefully this list can be used as a starting point for those looking for small-cap ideas.

All data sourced from Finviz. Full analysis below.



The list has been sorted by annual performance.

1. Global Ship Lease, Inc. (GSL): Shipping Industry. Market cap of $290.18M. The stock is currently 47.57% above its 20-day MA, 76.81% above its 50-day MA, and 106.02% above its 200-day MA. Short float at 3.34%, which implies a short ratio of 2.75 days. The stock has gained 400% over the last year.

2. Uroplasty Inc. (UPI):

By Alexander Moschina

It’s the future of cancer treatment. Plus, at just three feet tall, and weighing a mere 25 pounds, it’s also one of the smallest devices of its kind. In addition, it uses a fraction of the power used by other machines, but generates much higher temperatures. That means the doctors that use it can spend less money and kill more cancerous cells.

It also means that the tiny Salt Lake City company behind the device is making shareholders very rich. Since the FDA approved its revolutionary product on August 18, shares of this microcap are up 280%. And that’s just the beginning. It’s about to tap into a developing market that’s already worth billions…

BSD Pioneers the Future of Cancer Treatment

Since 1978, BSD Medical Corporation (Nasdaq: BSDM) has developed some of the world’s most revolutionary cancer treatments. In 2005, the company won the Frost &

As per their website Zoll Medical (ZOLL) is a leader in medical products and software solutions, helping responders manage, treat, and save lives in emergency rescues and in hospitals; outside the hospital while at work or home; in doctors' and dentists' offices and schools; in public places; and on the battlefield. ZOLL's products contribute to managing patient care and savings lives, as well as increasing the efficiency of emergency medical, fire and hospital operations around the globe.

When we look at the recent growth in EPS and sales for Zoll Medical we can see that their products are clearly in demand. During the past two quarters YOY EPS growth has been 113% (.17 compared to .08) and 271% (.26 compared to .07). Sales growth during the past four quarters YOY have increased 2%, 18%, 15%, and 17%. Even better, 2010 and 2011 EPS estimates are for gains of 89% and

By Marie Daghlian

Life sciences companies saw $3.4 billion in disclosed M&A transactions and $1.1 billion in disclosed partnering deals during the third week of August. Aspen Pharmacare’s (APNHF.PK) acquisition of the drugmaking assets of Sigma Pharmaceuticals for $806 million in cash will allow the troubled Australian pharmaceutical to clear its outstanding debt and focus on its pharmacy wholesale and retail division. The acquisition will make Aspen, Africa’s largest drugmaker, the largest prescription pharmaceuticals manufacturer in Australia. Aspen will acquire Herron and Orphan drug lines and manufacturing operations, as well as its generic and over-the-counter drug portfolios.

Two privately held contract research organizations were among the larger acquisition targets. Pharmacy benefits manager Medco Health Solutions agreed to buy United BioSource for $730 million in cash. United BioSource tests drugs and devices for safety and effectiveness after regulatory approval and has global resources.

The UBS acquisition follows Medco’s recent announcement

Below is a selection of companies with stock prices below $5 per share and upcoming binary events in the form of FDA decisions for medical device /diagnostic submissions to the Agency. A common strategy used by many investors is to buy a basket of several small or micro-cap companies (generally less than $1 billion market cap stocks) with pending binary events approximately 3-6 months ahead of the expected catalyst date and sell into the expected upward momentum in both stock price and trading volume.

Medical device and diagnostic submissions for FDA marketing clearance represent a unique niche within the space of trading binary events since there are no firm decision deadlines for decisions by the Agency and there is often a great deal of variability in the review periods. For example, Cambridge Medical (CAMH.OB) received marketing clearance for its Microvolt T-Wave Alternans OEM module used in cardiac stress testing systems

By Marie Daghlian
A couple of medical device companies closed significant financing rounds during a week when many members of the biotech community were wheeling and dealing in Chicago at the annual BIO International Convention. Atlanta-based CardioMEMS completed a $37.9 million financing that came from Arcapita Ventures and other existing investors. CardioMems is a digital health company developing wireless patient monitoring technology. The company will use the capital to complete its 550 patient CHAMPION clinical trial evaluating the safety and effectiveness of its heart failure pressure measurement system. Results are expected this summer.

CardioMEMS’ miniature sensor device is implanted in the patient’s pulmonary artery in a catheter-based procedure. The pulmonary artery pressure is then measured and displayed using an electronic monitoring system. The procedure allows patients to perform wireless measurements of their pulmonary artery pressure from home. Data is transmitted to a secure database and is available for

4:19 PM, Sep 29, 2009 --

• NYSE down 12.9 (0.2%) to 6,926.82.
• DJIA down 47.16 (0.5%) to 9,742.
• S&P 500 down 2.4 (0.2%) to 1,061.
• Nasdaq down 6.7 (0.3%) to 2,124.

GLOBAL SENTIMENT

• Hang Seng up 2.06%
• Nikkei up 0.91%
• FTSE down 0.12%

UPSIDE MOVERS

(+) CIT gains as report says top creditor eyeing merging company with IndyMac.

(+) C sells Portuguese card business to Barclays (BCS).

(+) WAG meets with Q4 results.

(+) MSHL says NV-128 mTOR inhibitor shows good safety profile.

(+) NVMI tapped for Foundry contract.

(+) RRI gets analyst upgrade.

(+) BSDM sells hyperthermia system.

(+) MRNA gets patent covering siRNA with therapeutic potential for oncology, other indications.

(+) DAL raises cash, improves liquidity.

(+) RL gets analyst upgrade.

DOWNSIDE MOVERS

(-) KERX reports positive study for Perifosine.

(-) SSTI hikes guidance.

(-) SQNM continues evening slide that followed independent inquiry results.

(-) RPRX gets further